Clinical evaluation of Cernilton in benign prostatic hypertrophy
Hayashi J, Mitsui H, Yamakawa G, Suga A, Kai A, Shimabukuro T, Yanagi K,
Fujisawa S, Takihara H, Kaneda Y, et al
Twenty patients with benign prostatic hypertrophy were treated with Cernilton,
6 tablets a day for an average of 13.2 weeks. Subjective effectiveness was
observed in the improvement of sense of residual urine (92%), retardation (86%),
night frequency (85%), strain on urination (56%), protraction (53%) and
forceless urinary stream (53%). The overall subjective effectiveness was 80% of
patients, and the overall objective effectiveness was 54% of patients. Night
frequency, residual urine volume and tidal urine volume were improved
significantly. The overall effectiveness was 80%. No side effects were observed.
PMID: 2421560, UI: 86183472